http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2787449-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8cfe0e04d0f35b242a9da5e036738b62 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4155 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-444 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4155 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2017-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-10-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_18920deea1a7cbe8206513295a0a5e1c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_46f28155cc6fe7ecc3ccd4aa02261054 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8e96a0fc0472b73b2598e8e7db132fba http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6bad1c0748ab8abca3dde0a227a0d285 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fdcdf6d2696b854ff3185095c6461680 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7404553a28ebb7d3f3e4b14c9e6209b6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eff3b573cbcf39869dc97b721e78a2dc |
| publicationDate | 2020-10-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2787449-T3 |
| titleOfInvention | Benzotriazole-derived unsaturated alpha and beta-amide compound used as TGF-betaRI inhibitor |
| abstract | A compound of formula (I) or a pharmaceutically acceptable salt thereof, ** (See formula) ** wherein, R1 is selected from hydrogen, hydroxyl, amino or from the group consisting of C1-3 alkyl and C3- cycloalkyl 6, and the group is optionally substituted with 1, 2, or 3 R; R2 is selected from the group consisting of C1-3 alkyl, C3-6 cycloalkyl, and phenyl, and the group is optionally substituted with 1, 2, or 3 R; R3 is selected from hydrogen or from C1-3 alkyl which is optionally substituted with 1, 2 or 3 R; optionally, R2 and R3 join to form a 5-6 membered ring, which is optionally substituted by 1, 2, or 3 R; each of R4 and R5 is independently selected from hydrogen, halogen, or selected from the group consisting of C1-3 alkyl and C1-3 heteroalkyl, and the group is optionally substituted with 1, 2, or 3 R; L is selected from a single bond, - (CRR) 1-3-; R- is selected from F, Cl, Br, I, CN, OH, NH2, COOH or from the group consisting of C1-6 alkyl, C1-6 heteroalkyl, C3-6 cycloalkyl, 3-6 membered heterocycloalkyl, phenyl and 5- to 6-membered heteroaryl, and the group is optionally substituted with 1, 2, or 3 R '; R 'is selected from F, Cl, Br, I, OH, CN, NH2, COOH, Me, Et, CF3, CHF2, CH2F, NHCH3, N (CH3) 2; "hetero" refers to a heteroatom or a heteroatomic group selected from the group consisting of -C (= O) N (R) -, -N (R) -, -C (= NR) -, -S (= O) 2N (R) -, -S (= O) N (R) -, -O-, -S-, = O, = S, -ON =, -C (= O) O-, -C ( = O) -, -C (= S) -, -S (= O) -, -S (= O) 2-, -N (R) C (= O) N (R) -; In any of the above cases, the number of the heteroatom or the heteroatomic group is independently selected from 1, 2 or 3. |
| priorityDate | 2016-06-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 322.